Researchers document link between higher risk of maternal mortality and sickle cell disease

Johns Hopkins Medicine researchers have further documented an association between a substantially higher risk of maternal morbidity and mortality among those with the inherited blood disorder sickle cell disease (SCD) compared to those without it. Their analysis, using a large national administrative database with records for pregnant people with SCD, found the maternal mortality rate was 26 times greater than the national average. This figure has not improved since the last time this population was assessed.

The study findings, published Feb. 2 in JAMA Network Open, highlight a need for increased disease-specific interventions for pregnant people with SCD, as well as health disparities long known to affect people with the disorder. In the United States, the condition is most prevalent in the Black community, according to the U.S. Centers for Disease Control and Prevention. In 2000 to 2003, the maternal mortality rate for people with sickle cell disease was 7.2 deaths per 10,000. In this study looking at data collected 15 years later, the mortality rate among pregnant people with SCD was 13.3 deaths per 10,000.

People with sickle cell disease are already lacking profoundly needed research and clinical care. Pregnant people with sickle cell disease are at an even greater disadvantage."

Lydia Pecker, M.D., assistant professor of medicine specializing in hematology at the Johns Hopkins University School of Medicine

In the new study, researchers applied the U.S. Centers for Disease Control and Prevention Severe Maternal Morbidity (SMM) index to the National Inpatient Sample -; a nationally representative sample of hospital admissions in the United States. Their analysis covered information collected from 2012–2018, which included 5,401,899 deliveries. This figure comprised 3,901 deliveries among pregnant people with SCD and 742,164 deliveries among Black people. Eighty-four percent of those with sickle cell disease who delivered were Black pregnant people.

Maternal mortality -; defined as death during pregnancy, at delivery, or soon after delivery -; was highest among those with SCD, at 13.3 per 10,000, compared to 1.2 per 10,000 among pregnant Black people and without SCD and 0.5 per 10,000 among non-Black, non-SCD patients during the study period.

"Pregnancy can bring out negative side effects of any pre-existing condition, and sickle cell disease is no exception," says Ahizechukwu Eke, M.B.Ch.B., Ph.D., M.P.H., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. "Sickle cell patients require more interventions, including increased blood transfusions and more frequent ultrasounds to assess the condition of the fetus."

The researchers noted that despite improvements in the care of people with SCD and improvements in the care of high-risk pregnancies, maternal mortality and morbidity rates of people with SCD have not improved. These findings suggest that advancements in SCD and high-risk OB care are not reaching enough pregnant people with SCD, the researchers say.

In the United States, 90% of people with SCD are Black, so pregnancies among people with SCD are often exposed to the harms of systemic and interpersonal racism. These factors contribute to high rates of maternal morbidity and mortality among pregnant Black Americans and, the investigators show, this also affects people with SCD.

"Our work demonstrates that people with sickle cell disease face risk over and above other pregnant people with Black race. Among the risks that are specific to people sickle cell disease are a highly morbid pre-existing condition, a lack of treatment options, in part due to the insufficient research focused on pregnant people with sickle cell disease, and to the absence of high-quality specialty care in many regions of the country," says Macy Early, fourth-year medical student at Johns Hopkins University School of Medicine, and lead author of this study.

SCD is an inherited blood disorder that is estimated to affect 70,000 to 100,000 Americans. The genetic alteration at the root of the disease affects red blood cells that contain hemoglobin, the protein responsible for transporting and delivering oxygen to the body, to become "sickled" in appearance. The disease not only causes anemia, strokes, organ damage and shortened life spans, but also repeated and frequent episodes of severe pain when the misshapen red blood cells get stuck in small blood vessels.

Although SCD is a lifelong debilitating illness, advances in treatment have led to nearly all affected people reaching their reproductive years in the United States. As such, there is a growing population of people impacted by the effects of SCD in pregnancy and study of possible treatments is needed. For the mother, SCD is linked to heightened risks of blood clots, chronic pain, anemia and preeclampsia (high blood pressure during pregnancy). The researchers confirmed that babies born to people with SCD tend to be smaller than average, delivered early and show damage to the placenta. Data from this study also affirm that SCD is associated with an increased risk of fetal death.

Researchers say they next plan to study data at the individual clinic level to analyze how outcomes for patients differ when high-quality OB care is accessible. They hope to accelerate research on risk and treatment during pregnancy, as well as continue to advocate for funding to ensure that all people in the United States receive high-quality care.

A companion paper to this study comparing outcomes in pregnant people with sickle cell disease and those with nutritional anemia was also published on Feb. 2 in JAMA Network Open.

Other scientists who contributed to this research are Alison Gemmill and Sophie Lanzkron of the Johns Hopkins University School of Medicine and Bloomberg School of Public Health.

This research was funded by the American Society of Hematology; the National Heart, Lung and Blood Institute; the National Institute of Child Health and Human Development; and the Mellon Foundation.

Lanzkron receives funding from Global Blood Therapeutics, Imara, Shire, Novartis and the National Institutes of Health (NIH); is a consultant for Bluebird Bio and Novo Nordisk; and holds stock in Pfizer and Teva. Gemmill is a consultant for the World Health Organization and Population Reference Bureau and receives funding from the NIH and the Robert Wood Johnson Foundation. The terms of these arrangements are managed by The Johns Hopkins University in accordance with its conflict of interest policies.